deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03296033

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery

Sponsor: Wake Forest University Health Sciences

Conditions Anticoagulants and Bleeding Disorders Regional Anesthesia Morbidity Surgery
Interventions Enoxaparin
Updated 13 times since 2017 Last updated: Sep 8, 2023 Started: Oct 24, 2017 Primary completion: Jan 14, 2022 Completion: Jan 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

enrollment proved to be a challenge due to the changing of the guidelines for bridging off the new anticoagulants that are being prescribed

Other terminated trials from Wake Forest University Health Sciences

See all terminations from Wake Forest University Health Sciences

Listed as NCT03296033, this PHASE4 trial focuses on Anticoagulants and Bleeding Disorders and Regional Anesthesia Morbidity and remains terminated or withdrawn. Sponsored by Wake Forest University Health Sciences, it has been updated 13 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jul 2019 · 11 months · monthly snapshot~Jul 2019 – ~Mar 2020 · 8 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jan 2022 · 10 months · monthly snapshot~Jan 2022 – ~Jan 2023 · 12 months · monthly snapshot~Jan 2023 – ~Nov 2023 · 10 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jan 2023 — Nov 2023 [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated

  5. Jan 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

▶ Show 8 earlier versions

  1. Mar 2021 — Jan 2022 [monthly]

    Recruiting PHASE4

  2. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE4

  3. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  4. Jul 2019 — Mar 2020 [monthly]

    Recruiting PHASE4

  5. Aug 2018 — Jul 2019 [monthly]

    Recruiting PHASE4

  6. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE4

  7. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  8. Oct 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wake Forest University Health Sciences
Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations